Changes to Brucella canis Serology Testing
On May 31st, 2022, the AHDC will implement the Canine Brucella Multiplex Assay to screen samples submitted for Brucella canis serology. The Canine Brucella Multiplex Assay uses a Luminex bead-based platform to detect antibodies directed against two Brucella-specific proteins for the serologic diagnosis of B. canis infection. The sensitivity of the Canine Brucella Multiplex Assay is estimated to be 95.3%. All samples that are negative in the Canine Brucella Multiplex Assay will be reported to the submitting veterinarian as ‘Negative’. For these samples, a rapid turn-around time with reporting of results within 1-2 working days can be expected.
All samples with non-negative results on the Canine Brucella Multiplex Assay will undergo confirmatory testing with the Canine Brucella Slide Agglutination/AGID II tests. The specificity of the Canine Brucella Slide Agglutination/AGID II combination testing is >99%. Results will be reported within 2-3 working days from the received date.
Samples submitted for regulatory purposes will be tested using the Canine Brucella Slide Agglutination/AGID II tests. Consult applicable regulatory guidelines or contact AHDC Regulatory Affairs for additional assistance in choosing the proper test to meet your specific requirements.
The fee for all Brucella canis serological testing will be $44/sample as of May 31st.